The global neurostimulation for chronic pain management market is driven by the increasing prevalence of chronic pain conditions, which affect a significant portion of the global population. It is estimated that around 20% of adults worldwide suffer from chronic pain, with back pain, neuropathic pain, and arthritis being among the most common types. In the United States alone, approximately 50 million adults are affected by chronic pain, creating a substantial demand for advanced pain management solutions. Neurostimulation therapies, particularly spinal cord stimulators (SCS) and peripheral nerve stimulators (PNS), are increasingly being adopted for their efficacy in treating refractory pain. The rise in the geriatric population, coupled with the growing awareness and acceptance of neurostimulation devices, further fuels the market. Additionally, advancements in technology, such as rechargeable neurostimulation devices, are enhancing the long-term effectiveness and patient comfort, positioning neurostimulation as a leading choice for chronic pain management.
